Company Overview and News
Sept 07, 2018 (LBO) – US Agency for International Development (USAID) has partnered with Sri Lankan banks to announce nine million US dollars worth financing program for micro, small and medium-sized enterprises (MSMEs).
• ‘Top 50’ Professional and Career Women Awards 2018 take inspiring stories of Sri Lankan women to the world • 63 remarkable women from Sri Lanka and Maldives recognized with Gold and Silver awards
The Central Bank has revised down the economic growth forecast for this year to 4 percent from the initial growth forecast of 5 - 5.5 percent at the beginning of the year, as the economic growth in the first half of the year is expected to have moderated to 3.4 percent. The International Monetary Fund (IMF) had also earlier forecasted a 4 percent economic growth for the island nation in 2018,while the World Bank had projected the economy to grow at 4.
The Monetary Board of the Central Bank of Sri Lanka yesterday decided to maintain policy interest rates at their current levels amidst monetary policy tightening in the United States and other major economies, strengthening of the US dollar, pressures on currencies of many emerging market economies and escalating trade tensions.
(PRESS RELEASE) – Sampath Bank’s Group pretax profit for the first half of the year exceeded Rs 10.3 Bn (28.2% growth) while Sampath Bank recorded a pre-tax profit of Rs 9.9 Bn for the same period. This registered a YoY growth of 28.1% in comparison to the first half of 2017. Profit after tax of the Bank too grew by 19.9% and reached Rs 6.8 Bn for the first half of 2018. Sampath Group, also posted a post-tax profit growth of 20.
July 26, 2018 (LBO) – Moody’s Investors Service has affirmed the local currency deposit ratings of Bank of Ceylon (BOC), Hatton National Bank Ltd. (HNB) and Sampath Bank PLC at B1/NP.
NDB Investment Bank (NDBIB)cemented its position as the market leader and premier Investment Bank in the country by being awarded as ‘Sri Lanka’s Best Investment Bank 2018’ by Euromoney Magazine.
Sampath Bank was recognized as Sri Lanka’s ‘Best Retail Bank’ and ‘Best Commercial Bank’for the 5th consecutive year at the prestigious World Finance Banking Awards awarded by UK based World Finance magazine.
Sampath Bank was recognized as Sri Lanka’s ‘Best Retail Bank’ and ‘Best Commercial Bank’ for the 5th consecutive year at the prestigious World Finance Banking Awards awarded by UK based World Finance magazine. Continuing to win accolades both within the island and around the world, the Bank has reigned supreme at this forum, bringing home the two awards, consistently, ever since 2014.
Jun 13, 2018 (LBO) – Fitch Ratings has affirmed the National Long-Term Rating of Sampath Bank at A+(lka) and revised the outlook to stable from negative.
Sampath Bank recommitted itself to offering technology driven, world class financial services to Sri Lankan consumers and businesses at an awe-inspiring event titled “Towards Vision 2020 with Sampath Stars” held at the Hilton Colombo, recently.
From left: Softlogic Holdings PLC Corporate Finance and Treasury Head Hiran Perera, HNB PLC Deputy General Manager Corporate Banking Ruwan Manatunga, Softlogic Holdings PLC Chairman and Managing Director Ashok Pathirage, Sampath Bank PLC Senior Deputy General Manager Corporate Banking Shashi Jassim and Bank of Ceylon PLC Deputy General Manager Corporate Banking and Offshore Banking Russel Fonseka
The Sri Lankan banks satisfy many of the key matrices such as growth, profits, efficiency and asset quality against most regional peers but the sector is in deep thirst for fresh capital as the banks brace for full implementation of BASEL III as early as in few months.
55BC CBQS HNB SAMP
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CSE:SAMP / SAMPATH BANK PLC on message board site Silicon Investor.